GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Luminex Corp (NAS:LMNX) » Definitions » ROC (Joel Greenblatt) %

Luminex (Luminex) ROC (Joel Greenblatt) % : 23.42% (As of Mar. 2021)


View and export this data going back to 2000. Start your Free Trial

What is Luminex ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Luminex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2021 was 23.42%.

The historical rank and industry rank for Luminex's ROC (Joel Greenblatt) % or its related term are showing as below:

LMNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7.69   Med: 29.52   Max: 43.09
Current: 25.63

During the past 13 years, Luminex's highest ROC (Joel Greenblatt) % was 43.09%. The lowest was -7.69%. And the median was 29.52%.

LMNX's ROC (Joel Greenblatt) % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -0.61 vs LMNX: 25.63

Luminex's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Luminex ROC (Joel Greenblatt) % Historical Data

The historical data trend for Luminex's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luminex ROC (Joel Greenblatt) % Chart

Luminex Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.88 35.72 22.12 -7.61 21.72

Luminex Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.54 38.50 23.07 20.82 23.42

Competitive Comparison of Luminex's ROC (Joel Greenblatt) %

For the Medical Instruments & Supplies subindustry, Luminex's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luminex's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Luminex's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Luminex's ROC (Joel Greenblatt) % falls into.



Luminex ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(66.963 + 123.134 + 9.527) - (37.48 + 10.047 + 33.992)
=118.105

Working Capital(Q: Mar. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(69.051 + 132.089 + 9.085) - (28.161 + 10.871 + 13.192)
=158.001

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Luminex for the quarter that ended in Mar. 2021 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2020  Q: Mar. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=52.756/( ( (81.914 + max(118.105, 0)) + (92.57 + max(158.001, 0)) )/ 2 )
=52.756/( ( 200.019 + 250.571 )/ 2 )
=52.756/225.295
=23.42 %

Note: The EBIT data used here is four times the quarterly (Mar. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Luminex  (NAS:LMNX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Luminex ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Luminex's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Luminex (Luminex) Business Description

Traded in Other Exchanges
N/A
Address
12212 Technology Boulevard, Suite 130, Austin, TX, USA, 78727
Luminex Corp develops, manufactures, and sells proprietary biological testing technologies and products to testing laboratories. It primarily serves the life sciences industries by selling products used by laboratory professionals and clinical laboratories in performing diagnostics, drug research and discovery, and clinical tests on patients. Luminex's market segments mainly include Infectious disease, Personalized medicine, and Human genetics. It offers various solutions in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. The vast majority of the company's revenue is earned in the United States. The products offered are xMAP Products, ARIES Products and VERIGENE Products, among others.
Executives
Harriss T Currie officer: SVP, Finance & CFO 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Todd C. Bennett officer: SVP, Global Sales & Cust Ops 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Stephen L. Eck director 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Edward A Ogunro director
Eric Shapiro officer: SR VP, GLOBAL MARKETING 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Nachum Shamir director, officer: President & CEO 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Rew Richard W. Ii officer: SVP, Gen Counsel & Corp Secy 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
Nancy Fairchild officer: SVP, Human Resources 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
G Walter Lowenbaum director C/O 3D SYSTEMS CORPORATION, 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730
Randall Myers officer: SVP, Global Mfg and Quality 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Charles J. Collins officer: SR VP, R&D - US 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Dijuana K Lewis director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Jim D Kever director C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Thomas W Erickson director OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Kenneth A Samet director 800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850

Luminex (Luminex) Headlines

From GuruFocus

Luminex Corporation Declares Fourth Quarter Cash Dividend

By PRNewswire PRNewswire 12-07-2020

Luminex Corporation Declares First Quarter Cash Dividend

By PRNewswire PRNewswire 02-08-2021

Luminex Corporation Pre-Release of 4th Quarter 2020 Revenue

By PRNewswire PRNewswire 01-12-2021